{"id":"W3011242490","doi":"10.1200/jco.2013.31.15_suppl.1050","title":"Quality of life (QoL) in patients (pts) with locally advanced or metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes who received eribulin mesylate or capecitabine: A phase III, open-label, randomized study.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Eribulin; Capecitabine; Internal medicine; Metastatic breast cancer; Clinical endpoint; Taxane; Quality of life (healthcare); Anthracycline; Breast cancer; Adverse effect; Oncology; Phases of clinical research; Progression-free survival; Cancer; Clinical trial; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001382952,0.000791372,0.001258318,0.0002428818,0.0003360892,0.0005754264,0.0003720431,0.0008931159,0.002420316],"category_scores_gemma":[0.001015795,0.0004220518,0.001261731,0.0004217089,0.000625268,0.0005225315,0.0003897953,0.001449656,0.0002820938],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005576536,"about_ca_system_score_gemma":0.0006568669,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000786103,"about_ca_topic_score_gemma":0.001280248,"domain_scores_codex":[0.9996411,0.0001969248,0.00002418674,0.00004631353,0.00003470762,0.00005681454],"domain_scores_gemma":[0.9993321,0.0001363452,0.0002175802,0.0000219181,0.00002561071,0.0002663861],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8269719,0.03887765,0.07364914,0.0008576066,0.002439815,0.0002080103,0.0002259842,0.001554098,0.007315966,0.0001242405,0.001209917,0.04656565],"study_design_scores_gemma":[0.3108136,0.5668272,0.116539,0.00006435979,0.001252047,0.0002264258,0.0001068184,0.001920279,0.0009320815,0.0001416935,0.001148931,0.00002762676],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9983826,0.0006807029,0.0001037144,0.00009699318,0.00002601675,0.0003192496,0.0001631616,0.000007448667,0.0002201471],"genre_scores_gemma":[0.9974312,0.0005260302,0.0003516392,0.0002437356,0.00005625407,0.0007290238,0.000318805,0.000002042783,0.0003412227],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002420316,"threshold_uncertainty_score":0.008096755,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.124413814494302,"score_gpt":0.5084301453302427,"score_spread":0.3840163308359407,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}